Static and dynamic mechanics of the murine lung after intratracheal bleomycin

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Manali, Effrosyni D ^a   Moschos, Charalampos ^a   Triantafillidou, Christina ^a   Kotanidou, Anastasia ^a   Psallidas, Ioannis ^a   Karabela, Sophia P ^a   Roussos, Charis ^a   Papiris, Spyridon ^a   Armaganidis, Apostolos ^a   Stathopoulos, Georgios T ^a   Maniatis, Nikolaos A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; SODIUM CHLORIDE;

AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CACHEXIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; HISTOLOGY; HYSTERESIS; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG INJURY; LUNG MECHANICS; LUNG STRUCTURE; LUNG VOLUME; MALE; MOUSE; NONHUMAN; OSCILLATION; PNEUMONIA; PRESSURE VOLUME CURVE; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; TISSUE VOLUME DENSITY; WEIGHT REDUCTION; ANIMAL; BREATHING MECHANICS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ELASTICITY; HOSPITALIZATION; INJECTION; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRACHEA;

AIRWAY RESISTANCE; ANIMALS; BLEOMYCIN; COLLAGEN; DISEASE MODELS, ANIMAL; ELASTICITY; INJECTIONS; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PULMONARY FIBROSIS; RESPIRATORY MECHANICS; SEVERITY OF ILLNESS INDEX; TRACHEA;

EID: 79957650380     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-33     Document Type: Article

References (44)

1. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009, 33:882-896. 10.1183/09031936.00152607, 19336591.
2. Antoniou KM, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008, 20:686-691. 10.1097/BOR.0b013e3283126985, 18946329.
3. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J 2007, 30:835-839. 10.1183/09031936.00069307, 17978154.
4. Ebihara T, Venkatesan N, Tanaka R, Ludwig MS. Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med 2000, 162:1569-1576.
5. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002, 83:111-119. 10.1046/j.1365-2613.2002.00220.x, 12383190.
6. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:899-907. 10.1164/rccm.200311-1535OC, 15618458.
7. Pottier N, Chupin C, Defamie V, Cardinaud B, Sutherland R, Rios G, Gauthier F, Wolters PJ, Berthiaume Y, Barbry P, et al. Relationships between early inflammatory response to bleomycin and sensitivity to lung fibrosis: a role for dipeptidyl-peptidase I and tissue inhibitor of metalloproteinase-3?. Am J Respir Crit Care Med 2007, 176:1098-1107. 10.1164/rccm.200607-1051OC, 17673693.
8. Dolhnikoff M, Mauad T, Ludwig MS. Extracellular matrix and oscillatory mechanics of rat lung parenchyma in bleomycin-induced fibrosis. Am J Respir Crit Care Med 1999, 160:1750-1757.
9. Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol 2007, 37:300-308. 10.1165/rcmb.2007-0057OC, 1994226,1994226, 17496151.
10. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005, 33:9-13. 10.1165/rcmb.2005-0062TR, 15964990.
11. Gauldie J, Kolb M. Animal models of pulmonary fibrosis: how far from effective reality?. Am J Physiol Lung Cell Mol Physiol 2008, 294:L151.
12. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol 2008, 40:362-382. 10.1016/j.biocel.2007.08.011, 2323681, 17936056.
13. Goldstein RH, Lucey EC, Franzblau C, Snider GL. Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 1979, 120:67-73.
14. Bates JH, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003, 94:1297-1306.
15. Gomes RF, Shen X, Ramchandani R, Tepper RS, Bates JH. Comparative respiratory system mechanics in rodents. J Appl Physiol 2000, 89:908-916.
16. Pinart M, Serrano-Mollar A, Negri EM, Cabrera R, Rocco PR, Romero PV. Inflammatory related changes in lung tissue mechanics after bleomycin-induced lung injury. Respir Physiol Neurobiol 2008, 160:196-203. 10.1016/j.resp.2007.09.012, 17981520.
17. Hantos Z, Daroczy B, Suki B, Nagy S. Low-frequency respiratory mechanical impedance in the rat. J Appl Physiol 1987, 63:36-43.
18. Hantos Z, Daroczy B, Suki B, Nagy S, Debreczeni LA. Respiratory mechanical impedance in the rat. Acta Physiol Hung 1987, 70:289-296.
19. Cohen JC, Lundblad LK, Bates JH, Levitzky M, Larson JE. The "Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genet 2004, 5:21. 506778, 15279681.
20. Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Crit Care Med 2008, 177:1314-1321. 10.1164/rccm.200708-1141OC, 18356565.
21. Tomioka S, Bates JH, Irvin CG. Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol 2002, 93:263-270.
22. Haston CK, Amos CI, King TM, Travis EL. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res 1996, 56:2596-2601.
23. Haston CK, Tomko TG, Godin N, Kerckhoff L, Hallett MT. Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet 2005, 42:464-473. 10.1136/jmg.2004.027938, 1736068, 15937080.
24. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, King TM, Weil MM, Newman RA, Amos CI, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 2002, 11:1855-1863. 10.1093/hmg/11.16.1855, 12140188.
25. Lewis CC, Yang JY, Huang X, Banerjee SK, Blackburn MR, Baluk P, McDonald DM, Blackwell TS, Nagabhushanam V, Peters W, et al. Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med 2008, 177:376-387. 2258439, 18029791.
26. Tran PL, Weinbach J, Opolon P, Linares-Cruz G, Reynes JP, Gregoire A, Kremer E, Durand H, Perricaudet M. Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest 1997, 99:608-617. 10.1172/JCI119203, 507842, 9045862.
27. Grimby G, Takishima T, Graham W, Macklem P, Mead J. Frequency dependence of flow resistance in patients with obstructive lung disease. J Clin Invest 1968, 47:1455-1465. 10.1172/JCI105837, 297301, 5653219.
28. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005, 171:261-268.
29. Lemay AM, Haston CK. Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. Physiol Genomics 2005, 23:54-61. 10.1152/physiolgenomics.00095.2005, 16179420.
30. Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M. Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999, 20(4):825-833.
31. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 1983, 127(1):63-66.
32. Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology (Oxford) 2008, 47(Suppl 5):v48-50.
33. Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2006, 291(2):L144-156. 10.1152/ajplung.00492.2005, 16473862.
34. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken E, Decramer M, Nemery B, et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol 2010, 42(1):96-104. 10.1165/rcmb.2008-0487OC, 19346316.
35. Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res 11(1):34.
36. Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 1995, 98(1-3):163-175. 10.1016/0300-483X(94)02987-6, 7537925.
37. Polosukhin VV, Stathopoulos GT, Lawson WE, Blackwell TS. Variability of interalveolar septal remodeling after bleomycin treatment in mice. Ultrastruct Pathol 2005, 29(1):53-64. 10.1080/019131290882286, 15934165.
38. Bates JH, Davis GS, Majumdar A, Butnor KJ, Suki B. Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med 2007, 176(6):617-623. 10.1164/rccm.200611-1739OC, 1994222, 17575096.
39. Suki B, Bates JH. Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol 2008, 163(1-3):33-43. 10.1016/j.resp.2008.03.015, 2666313, 18485836.
40. Bates JH. Point:Counterpoint: lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol 2007, 103(5):1900-1901. discussion 1904, 10.1152/japplphysiol.00369.2007, 17431089.
41. Wagers S, Lundblad LK, Ekman M, Irvin CG, Bates JH. The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?. J Appl Physiol 2004, 96(6):2019-2027. 10.1152/japplphysiol.00924.2003, 14660507.
42. Mitzner W. Counterpoint: lung impedance measurements are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol 2007, 103(5):1901-1903. discussion 1903-1904, 10.1152/japplphysiol.00369.2007a, 17965240.
43. Cavarra E, Carraro F, Fineschi S, Naldini A, Bartalesi B, Pucci A, Lungarella G. Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol 2004, 287(6):L1186-1192. 10.1152/ajplung.00170.2004, 15321784.
44. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 1999, 54(5):390-395. 10.1136/thx.54.5.390, 1763791, 10212101.